Search
shopping
Search
Menu

Goal and Learning Outcomes

The goal of this urinalysis continuing education course is to provide laboratory professionals, CMAs, and nurses with a comprehensive review of microscopic urinalysis. After taking this course, you should be able to:
  • Describe the methods necessary for preparing urine samples for microscopic examination.
  • Identify the structures and cells present during a microscopic examination of urine sediment.
  • Identify the disease states associated with microscopic urine findings and those structures found in healthy samples.
  • Describe the preferable methods for urine collection from males, females, and infants, including when patients have indwelling catheters or cannot void on their own.
  • Discuss how the healthcare team can work better together to enhance proper laboratory specimen collection.

Course Authors

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.